Cell replication Folate transfers single carbon atoms in reactions essential to the

synthesis of purines and pyrimidines and hence to the production of deoxyribonucleic acid

(DNA). Unlike the methylation cycle, the DNA cycle does not depend on vitamin B12. Folic

acid can thus maintain the supply of intracellular folate required for DNA synthesis. DNA

synthesis, and hence cell replication, can therefore take place in people with vitamin B12

deficiency, provided that folic acid is available as a source of folate.

42 Rossana Salerno-Kennedy

A number of drugs interfere with the biosynthesis of folic acid and tetrahydrofolate.

Among these are the dihydrofolate reductase inhibitors (such as trimethoprim and

pyrimethamine), the sulfonamides (competitive inhibitors of para-aminobenzoic acid in the

reactions of dihydropteroate synthetase), and the anticancer drug methotrexate (inhibits both

folate reductase and dihydrofolate reductase).

DIETARY SOURCES

Naturally occurring folate is found in a wide variety of foods, including green leafy

vegetables, liver, kidneys, grains, bread and nuts. Folates are extremely unstable. Sensitive to

light, heat and oxygen, they rapidly lose activity in foods during harvesting, storage,

preparation and processing.

By contrast, synthetic folic acid, which is added to various foods during fortification (as

well as dietary supplements), is stable for months or even years. It is also more than 90 per

cent bioavailable, compared with folates in foods which are only about 45 % bioavailable.

RDI

The Reference Daily Intake (RDI) is the average daily dietary intake level that is

sufficient to meet the nutrient requirements of nearly all (97% to 98% of) healthy individuals

in each life-stage and gender group. The 1998 RDIs for folate are expressed in a term called

the "dietary folate equivalent" (DFE). This was developed to help account for the differences

in absorption of naturally-occurring dietary folate and the more bioavailable synthetic folic

acid [19]. The 1998 RDAs for folate expressed in micrograms (µg) of DFE for adults are:

1998 RDAs for Folate

Men Women

(19+) (19+) Pregnancy Breast feeding

400 µg 400 µg 600 µg 500 µg

1 µg of food folate = 0.6 µg folic acid from supplements and fortified foods

CLINICAL DEFICIENCY

The main causes of folate deficiency are:

• Decreased dietary intake - This occurs in people eating inadequate diets, such as

some elderly people, some people on low incomes, and alcoholics who substitute

alcoholic drinks for good sources of nutrition

• Decreased intestinal absorption - Patients with disorders of malabsorption (e.g.,

coeliac disease) may suffer folate deficiency

Folic Acid and Health: An Overview 43

• Increased requirements - Increased requirement for folate, and hence an increased

risk of deficiency, can occur in pregnancy, during lactation, in haemolytic anaemia

and in leukaemia

• Alcoholism - Chronic alcoholism is a common cause of folate deficiency. This may

occur as a result of poor dietary intake or through reduced absorption or increased

excretion by the kidney. The presence of alcoholic liver disease increases the

likelihood of folate deficiency

• Drugs - Long term use of certain drugs (e.g., phenytoin, sulphasalazine) is associated

with folate deficiency.

Folate deficiency has also been associated with neural tube defects [1], cardiovascular

disease [2], cancer of various sites [3], depression [4], dementia [5], and osteoporosis [6,7].

FOLIC ACID AND PREGNANCY

The traditional view that the only concern in relation to folate status was clinical

deficiency was challenged when it became clear that the risk of congenital malformations,

including neural tube defects (NTDs), could be reduced by increased folic acid intake during

the periconceptional period [13]. Neural tube defects result in malformations of the spine

(spina bifida), skull, and brain (anencephaly) [9]. Since the discovery of the link between

insufficient folic acid and neural tube defects (NTDs), governments and health organisations

worldwide have made recommendations concerning folic acid supplementation for women

intending to become pregnant [20]. It was suggested to take 400 micrograms of synthetic

folic acid daily from fortified foods and/or supplements [21]. This has also led to the

introduction in many countries of fortification, where folic acid is added to flour with the

intention of everyone benefiting from the associated rise in blood folate levels [20]. In

countries where mandatory fortification of flour was introduced, folate and homocysteine

status improved notably and neural tube defect rates fell by up to nearly 80% [20]. Despite

public-health campaigns, knowledge about the proper periconceptional time to use folic acid

supplements for the prevention of neural tube defects is not widespread in women and only a

maximum of half of them are following the recommendations [20]. Vulnerable groups are

people of low educational status, young people, immigrants, and women with unplanned

pregnancies. A substantial percentage of women still choose not to take the supplements even

though they are aware of the beneficial effects [20].

Why folic acid should influence the incidence of neural tube defects remains unclear.

Neural tube defects almost certainly occur as a result of complex genetic, nutritional and

environmental interactions, and some interesting clues have emerged in the area of genetics.

A defect in the methylene-tetrahydrofolate-reductase (MTHFR) gene, which occurs in about

5 to 15 per cent of white populations, has been identified [22]. This genetic defect appears to

result in an increased requirement for folates and an increased risk of recurrent early

pregnancy loss and NTDs [23]. In addition, elevated levels of plasma homocysteine have

been observed in mothers producing offspring with NTDs [24]. The possibility that this factor

could have toxic effects on the foetus at the time of neural tube closure is currently under

44 Rossana Salerno-Kennedy

further investigation. Although folic acid does reduce the risk of birth defects, it is only one

part of the picture and should not be considered a cure. Even women taking daily folic acid

supplements at the reccomended dose have been known to have children with neural tube

defects [20].

FOLIC ACID AND CARDIOVASCULAR DISEASE

Low concentrations of folate, vitamin B12, or vitamin B6 may increase the plasma level of

the aminoacid Homocysteine (Hcy). As explained previously, homocysteine is derived from

dietary methionine, and is removed by conversion to cystathionine, cysteine and pyruvate, or

by remethylation to methionine.

There is evidence that an elevated homocysteine level is an independent risk factor for

cardiovascular disease (CVD) mortality [25-27]. Mechanisms by which plasma Hcy may be

associated with an increased risk of CVD have not been clearly established, but possibilities

include [28]:

• Oxidative damage to the vascular endothelium

• Inhibition of endothelial anticoagulant factors, resulting in increased clot formation

• Increased platelet aggregation

• Proliferation of smooth muscle cells, resulting in increased vulnerability of the

arteries to obstruction

An increased level of plasma Hcy may be caused by rare inborn errors of its metabolism.

An example is homocystinuria, which occurs as a result of a genetic defect in the enzyme

cystathione synthase. Genetic changes in the enzymes involved in the remethylation pathway,

including methylene tetrahydrofolate reductase and methionine synthase, are also associated

with an increase in plasma homocysteine concentrations. All such cases are associated with

premature vascular disease, thrombosis and early death. Such genetic disorders are rare and

cannot account for the raised homocysteine levels observed in many patients with

cardiovascular disease. However, attention is now being given to the possibility that

deficiency of the various vitamins which act as co-factors for the enzymes involved in

homocysteine metabolism could result in increased Hcy concentrations. In particular, folate is

required for the normal function of methylene-tetrahydrofolate-reductase, vitamin B12 for

methionine-synthase and vitamin B6 for cystathione-synthase.

In theory, lack of any one of these three vitamins could cause hyperhomocysteinaemia,

and could therefore increase the risk of cardiovascular disease [28]. In the Framingham Heart

Study [29], the longest observed cohort study on vascular disease, it was shown that folic

acid, vitamin B6 and vitamin B12 are determinants of plasma homocysteine levels, with folic

acid showing the strongest association.

The question whether increased vitamin intake can reduce cardiovascular disease risk

was examined in the Nurse's Health Study [30]. The results showed that those with the

highest intake of folate had a 31 % lower incidence of heart disease than those with the

lowest intake. Those with the highest intake of vitamin B6 had a 33 % lower risk of heart

Folic Acid and Health: An Overview 45

disease, while in those with the highest intake of both vitamin B6 and folate, the risk of heart

disease was reduced by 45 %. The risk of heart disease was reduced by 24 % in those who

regularly used multivitamins.

Another question is whether homocysteine levels can be lowered with folate and other B

vitamins. Studies have shown that folic acid (250μg daily), in addition to usual dietary

intakes of folate, significantly decreased plasma homocysteine concentrations in healthy

young women [31]. Breakfast cereal fortified with folic acid reduced plasma homocysteine in

men and women with coronary artery disease [32].

Another study has demonstrated that the addition of vitamin B12 to either folic acid

supplements or enriched foods (400μg folic acid daily) maximizes the reduction of

homocysteine [33]. Furthermore, two meta-analyses [34, 35] suggest that the administration

of folic acid reduces plasma homocysteine concentrations and that vitamin B12, but not

vitamin B6, may have an additional effect [35].

On the other hand, the NORVIT trial [36] has suggested that folic acid supplementation

may do more harm than good. As of 2006, studies have shown that giving folic acid to reduce

levels of homocysteine does not result in clinical benefit and have suggested that in

combination with B12 it may even increase some cardiovascular risks [36,37].

Unfortunately, a definitive answer to the most important question of whether or not

reducing homocysteine can reduce cardiovascular disease does not yet exist due to the lack of

published data. However, there is currently no evidence available to suggest that lowering

homocysteine with vitamins will reduce the risk of heart disease. Clinical intervention trials

are needed to determine whether supplementation with folic acid, vitamin B12 or vitamin B6

can lower the risk of developing coronary heart disease.

FOLIC ACID AND MENTAL DISORDERS

There is an apparent increase in mental disorders associated with reduced folate status

[38]. However, whether this reduced vitamin status is a cause of the disease, or occurs as a

result of having the disease, is unknown.

Studies have found that Alzheimer's disease (AD) is associated with low blood levels of

folate and vitamin B12 and elevated homocysteine (Hcy) levels [39, 40]. In particular, the

long-running Framingham Study, has shown that people with hyperhomocysteinemia (Hcy

>14 μmol/l) had nearly double the risk of developing AD [41]. This study was the first to

associate Hcy levels, measured several years earlier, with later diagnosis of AD and other

dementias. Furthermore, the association between Hcy and AD was found to be strong and

independent of other factors, such as age, gender, APOE genotype, and other known or

suspected risk factors for dementia and AD. Clarke et al. [42] have also shown that low

serum folate and consequently elevated concentrations of serum Hcy, was associated with

progressive atrophy of the medial temporal lobe in subjects with AD. The serum folate

seemed to have a strong negative association with the severity of atrophy of the neocortex in

the “Nun Study”, suggesting that atrophy may be specific to relatively low folate

concentrations [43]. Therefore, the relationship between Hcy and dementia is of particular

46 Rossana Salerno-Kennedy

interest because blood levels of Hcy might be reduced by increasing the intake of folic acid

and vitamins B6 and B12.

The recent Baltimore Longitudinal Study of Aging on 579 older individuals without

dementia (follow-up of 9.3 years) has suggested that consuming levels of folate at or above

RDA (400 micrograms) is associated with a reduced risk of AD [44]. It has also been

suggested that a fortification policy based on folic acid and vitamin B12, rather than folic acid

alone, is likely to be much more effective at lowering Hcy concentrations, with potential

benefits for reducing the risk of AD and vascular disease [44].

Comments

Search This Blog

Archive

Show more

Popular posts from this blog

TRIPASS XR تري باس

CELEPHI 200 MG, Gélule

ZENOXIA 15 MG, Comprimé

VOXCIB 200 MG, Gélule

Kana Brax Laberax

فومي كايند

بعض الادويه نجد رموز عليها مثل IR ، MR, XR, CR, SR , DS ماذا تعني هذه الرموز

NIFLURIL 700 MG, Suppositoire adulte

Antifongiques مضادات الفطريات

Popular posts from this blog

علاقة البيبي بالفراولة بالالفا فيتو بروتين

التغيرات الخمس التي تحدث للجسم عند المشي

إحصائيات سنة 2020 | تعداد سكَان دول إفريقيا تنازليا :

ما هو الليمونير للأسنان ؟

ACUPAN 20 MG, Solution injectable

CELEPHI 200 MG, Gélule

الام الظهر

VOXCIB 200 MG, Gélule

ميبستان

Popular posts from this blog

TRIPASS XR تري باس

CELEPHI 200 MG, Gélule

Popular posts from this blog

TRIPASS XR تري باس

CELEPHI 200 MG, Gélule

ZENOXIA 15 MG, Comprimé

VOXCIB 200 MG, Gélule

Kana Brax Laberax

فومي كايند

بعض الادويه نجد رموز عليها مثل IR ، MR, XR, CR, SR , DS ماذا تعني هذه الرموز

NIFLURIL 700 MG, Suppositoire adulte

Antifongiques مضادات الفطريات

Popular posts from this blog

Kana Brax Laberax

TRIPASS XR تري باس

PARANTAL 100 MG, Suppositoire بارانتال 100 مجم تحاميل

الكبد الدهني Fatty Liver

الم اسفل الظهر (الحاد) الذي يظهر بشكل مفاجئ bal-agrisi

SEDALGIC 37.5 MG / 325 MG, Comprimé pelliculé [P] سيدالجيك 37.5 مجم / 325 مجم ، قرص مغلف [P]

نمـو الدمـاغ والتطـور العقـلي لـدى الطفـل

CELEPHI 200 MG, Gélule

أخطر أنواع المخدرات فى العالم و الشرق الاوسط

Archive

Show more